Navigation Links
BioMS Medical announces second quarter 2009 results
Date:7/17/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, July 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the three and six months ended June 30, 2009.

"The pivotal phase III MAESTRO-01 trial has completed the last patient last visit, and we are expecting results from this study within the second half of this year. This is the first of our two pivotal trials evaluating dirucotide in patients with secondary progressive multiple sclerosis and with a positive outcome, our drug could represent a valuable new treatment for MS patients," said Kevin Giese, President and CEO of BioMS Medical.

Currently, BioMS is conducting two pivotal clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

    -   MAESTRO-01: This pivotal phase III trial is being conducted in Canada
        and Western Europe, involving 611 SPMS patients at 47 trial sites in
        ten countries. The primary clinical endpoint for MAESTRO-01 (and
        MAESTRO-03) is defined as a statistically and clinically significant
        increase in the time to progression of the disease as measured by the
        Expanded Disability Status Scale (EDSS), in patients with HLA-DR2
        and/or HLA-DR4 immune response genes.

    -   MAESTRO-02: Eligible patients who have successfully completed
        MAESTRO-01 may choose to receive dirucotide on an un-blinded basis in
        this open-label follow-on study regardless of whether they were
        previously on placebo or drug. To date, approximately 95% of the
        eligible patients who have successfully completed the MAESTRO-01
        trial have enrolled in this follow-on study.

    -   MAESTRO-03: Enrollment was initiated in June 2007 and completed on
        August 1, 2008 for this pivotal U.S. phas
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
2. BioMS Medical to participate in panel session at Bio International Convention 2009
3. BioMS Medical Announces First quarter 2009 results
4. BioMS Medical to present at Alberta Economic Forum in Geneva
5. BioMS Medical to present at BioFinance 2009
6. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
8. BioMS Medical Announces 2008 Year End Results
9. BioMS Medical warrant extension
10. BioMS Medical to present at BIO CEO and Investor Conference
11. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... ... 2015 , ... Inc. Magazine released its annual list of the 5,000 fastest-growing ... growth for the three years through 2014. Being named to the Inc. 5000 list ... the country. , “We are thrilled to make the Inc. 5000 list for ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... in Personalized Medicine, recently presented new data on the relationship of genetics and ... 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, ...
(Date:8/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, today announced that ... & Company Emerging Growth Conference on September 2 at ... New York Marriott Marquis. A live ... investor relations section of Roka Bioscience,s website at ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3
... Mich., Feb. 5 Energy,Conversion Devices, Inc. (ECD) (Nasdaq: ... United Solar Ovonic LLC and United Solar Ovonic,Corporation, have ... aggregate commitment of up to $55 million, pursuant to ... Agreement, each with,JPMorgan Chase Bank, N.A. The new credit ...
... Feb. 5 GeneGo, Inc., the leading,systems biology ... their,licensing agreement with GeneGo and have added additional ... and clinical studies,with global access to MetaCore, MapEditor ... analysis of biological OMICs data,featuring a comprehensive collection ...
... 5 DiObex, Inc., a privately held,biotechnology company focused ... today that CEO David Cory will deliver a,corporate presentation ... Biotechnology and Medical Device Conference in New York,New York. ... 6 at,10:20 a.m. at the Grand Hyatt Hotel in ...
Cached Biology Technology:Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements 2GSK Extends GeneGo License and Adds New Products 2
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... major infectious disease today. It is estimated that two ... without active symptoms. Nine million new cases of active ... TB is predominantly a lung disease. It is caused ... cells, but it is still not clear how exactly ...
... the flatworm, planaria, offers new clues for understanding ... Institute have discovered how the worm's cells communicate ... scientists have found that gap-junction (microscopic tunnels directly ... This research, led by Dr. Michael Levin, underlies ...
... in ocean-bottom sediments appears in laboratory tests to ... cells, and potentially with less toxicity than current ... November issue of Cancer Cell. , The experimental ... inhibit cancer cells' proteasomes from working effectively. The ...
Cached Biology News:How does Mycobacterium tuberculosis infect the lung? 2New understanding of regeneration gained by Forsyth scientists 2Compound from marine bacteria shows potential as multiple myeloma therapy 2Compound from marine bacteria shows potential as multiple myeloma therapy 3
... is used in conjunction with ... of problematic and/or GC-rich templates ... with 10X PCRX Amplification Buffer ... magnesium concentration broader annealing temperature ...
MAGP-2 (C-19)...
Fibulin-2 (D-15)...
UCP1/2/3 (FL-307)...
Biology Products: